Allergan, Author Interviews, Bipolar Disorder, Mental Health Research / 23.05.2019 Interview with: [caption id="attachment_49298" align="alignleft" width="200"]Dr. Stephen Stahl MD PhDProfessor of Psychiatry University of California San Diego Dr. Stahl[/caption] Dr. Stephen Stahl MD PhD Professor of Psychiatry University of California San Diego What is the background for this study? How does cariprazine differ from other medications for bipolar depression? It is important to note that cariprazine, a dopamine D3-preferring D3/D2 receptor and serotonin 5-HT1A receptor partial agonist, is approved for the treatment of schizophrenia (1.5-6 mg/d) and bipolar mania (3-6 mg/d) in adults. It is not yet approved for depressive episodes related to bipolar I disorder (bipolar depression). In these data that focus on the investigational use for the treatment of bipolar depression, cariprazine has demonstrated efficacy vs placebo (PBO) in 3 phase 2/3 studies of patients with bipolar depression (NCT01396447, NCT02670538, NCT02670551). These analyses investigated the efficacy of cariprazine in patients with bipolar depression and concurrent manic symptoms (mixed features).